SCHEMBL13877426

SCHEMBL13877426

c1ccc(-c2ccc3c(c2)c2cc(-c4ccccc4)ccc2n3-c2nc(-n3c4ccc(-c5ccccc5)cc4c4cc(-c5ccccc5)ccc43)c3ccccc3n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 4/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ GLA P06280 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ EGLN1 Q9GZT9 8/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ACP1 P24666 2/20 0.36
▸ DHODH Q02127 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ TRIM58 Q8NG06 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16475859 0.89 L3MBTL1 (0.47) HPGDL3MBTL1GLAGAATSHR
SCHEMBL15395025 0.89 L3MBTL1 (0.47) HPGDL3MBTL1GLAGAATSHR
SCHEMBL18589272 0.89 L3MBTL1 (0.47) HPGDL3MBTL1GLAGAATSHR
SCHEMBL15394871 0.86 L3MBTL1 (0.44) HPGDL3MBTL1GLAGAATSHR
SCHEMBL15395057 0.86 L3MBTL1 (0.44) HPGDL3MBTL1GLAGAATSHR
SCHEMBL15394872 0.86 L3MBTL1 (0.44) HPGDL3MBTL1GLAGAATSHR
SCHEMBL18505395 0.85 ALDH1A1 (0.55) HPGDL3MBTL1GAAKDM4EALDH1A1
SCHEMBL19102541 0.84 L3MBTL1 (0.40) HPGDL3MBTL1GLAGAATSHR
SCHEMBL24296784 0.84 ALDH1A1 (0.42) HPGDL3MBTL1GAAKDM4EALDH1A1
SCHEMBL20232134 0.84 ALDH1A1 (0.54) HPGDL3MBTL1GAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090091240-A1 COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2009-04-09 — — US disclosed
US-20090091240-A1 COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2009-04-09 — — US disclosed
EP-1808433-A1 COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN COMPANY LIMITED (JP) 2007-07-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090091240-A1 COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME INTS9, KCNN2, KCNH3 HPGD 4019/4885L3MBTL1 2009/4885GLA 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback